PA
VNDA icon

Perceptive Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Perceptive Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-36,232
Closed -$649K – 153
2017
Q3 		$649K Hold
36,232
– – 0.02% 112
2017
Q2 		$591K Hold
36,232
– – 0.03% 110
2017
Q1 		$507K Buy
+36,232
New +$516K 0.03% 121
2016
Q2 		– Sell
-71,849
Closed -$601K – 201
2016
Q1 		$601K Hold
71,849
– – 0.05% 108
2015
Q4 		$669K Buy
+71,849
New +$717K 0.05% 93
2013
Q4 		– Sell
-868,500
Closed -$9.51M – 132
2013
Q3 		$9.51M Buy
+868,500
New +$9.28M 0.77% 35

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors's VNDA Position: Q4 2017 in Review

Perceptive Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2017, closing a stake of 36,232 shares — an estimated $649K sold.

Perceptive Advisors first reported a position in VNDA in Q3 2013 and held it in 6 quarters. The position peaked at $9.51M in Q3 2013. 125 funds tracked by Wall St. Rank hold VNDA as of Q4 2017.

  • Perceptive Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 36,232 Vanda Pharmaceuticals shares in Q4 2017, an estimated $649K.
  • Perceptive Advisors first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Perceptive Advisors's Vanda Pharmaceuticals position peaked at $9.51M in Q3 2013.
  • 125 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.